{
  "success": true,
  "applicability": {
    "isApplicable": false,
    "reasons": [
      {
        "type": "condition",
        "description": "Patient does not have required condition: atherosclerotic cardiovascular disease",
        "details": "The study required patients to have atherosclerotic cardiovascular disease"
      },
      {
        "type": "medication",
        "description": "Patient is not on required medication: statin therapy",
        "details": "The study required patients to be taking statin therapy"
      }
    ]
  },
  "patientSummary": {
    "age": 42,
    "sex": "male",
    "relevantBiomarkers": [
      {
        "name": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay",
        "value": "110",
        "unit": "mg/dL",
        "date": "2023-03-07T16:18:17.000Z"
      }
    ],
    "relevantConditions": [],
    "relevantMedications": [
      "valACYclovir 500 MG Oral Tablet",
      "loratadine (CLARITIN) 10 mg tablet",
      "valACYclovir 500 MG Oral Tablet",
      "SUMAtriptan succinate 25 MG Oral Tablet",
      "ondansetron HCl 4 MG Oral Tablet",
      "rizatriptan benzoate 10 MG Oral Tablet",
      "valACYclovir 500 MG Oral Tablet",
      "amoxicillin 875 MG Oral Tablet",
      "levoFLOXacin 500 MG Oral Tablet",
      "Claritin",
      "Vitamin D",
      "Nurtec ODT 75 MG Disintegrating Oral Tablet",
      "Maxalt 10 MG Oral Tablet",
      "rimegepant 75 MG Disintegrating Oral Tablet",
      "valACYclovir 500 MG Oral Tablet",
      "loratadine 10 MG 24HR Oral Capsule",
      "levoFLOXacin 500 MG Oral Tablet",
      "valACYclovir 500 MG Oral Tablet"
    ]
  },
  "paperSummary": {
    "intervention": "evolocumab (either 140 mg every 2 weeks or 420 mg monthly)",
    "primaryEndpoint": "composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization",
    "population": "Patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy.",
    "followUp": "2.2 years median"
  }
}